JHOP - June 2016 Vol 6, No 2
Lillian Smith, PharmD, MBA, CPh, Juan Mosley, PharmD, CPh, AAHIVP, Megan Ford, PharmDc, Jonathan Courtney, PharmDc
Determination of Extended Sterility for Single-Use Vials Using the PhaSeal Closed-System Transfer Device
Kristin V. Ho, PharmD, BCOP, Michael S. Edwards, PharmD, MBA, BCOP, FASHP, Dominic A. Solimando, Jr, MA, BCOP, FAPhA, FASHP, Anthony D. Johnson, CPhT
Austin J. Combest, PharmD, BCOP, MBA, Ryan C. Danford, PharmD, Elizabeth R. Andrews, PharmD, Ashley Simmons, PharmD, Paulina McAtee, PharmD, Dirk J. Reitsma, MD
From 2005 to 2014, the number of ongoing trials of chronic lymphocytic leukemia (CLL) has increased at a compound annual growth rate of 18.4%. This rapid growth in the CLL clinical trial landscape has led to multiple breakthroughs in the management of CLL, which have changed—and will continue to change—the treatment paradigm in the near future.
Results 1 - 4 of 4